ACE inhibition in the tissues.
The discovery of the components of the renin angiotensin system (RAS) in various tissues gave rise to the idea that functional "tissue" renin-angiotensin systems exist that are more or less independent of the hormonal RAS. Further support to this notion came from the recent demonstration of the mRNA for the protein components of the RAS in a number of organs. Last not least, the introduction of the CE inhibitors, generating an enormous scientific interest in the role of the RAS, has contributed to the concept of "tissue" RAS, since some of the effects of these drugs were thought to be reconciled better with "tissue" than with plasma RAS inhibition. However, this model of plasma vs "tissue" RAS still suffers from a number of conceptual problems that have to be dealt with. For instance, with respect to the "tissue" RAS in the vascular wall it is not clear at present whether ACE is at all active inside endothelial cells. In addition, all evidence available speaks against its localisation in the vascular media, while there may be some activity of the enzyme in the adventitial layer. Concerning the heart, there is at present no unequivocal evidence for a local ANG II production through angiotensin converting enzyme (ACE) in cardiac tissue outside the coronary vessels. The localisation of ANG II generation within tissue RAS in the adrenal gland or in the kidney, where ANG II may be generated through CE at the tubular brush border, is far from being elucidated.(ABSTRACT TRUNCATED AT 250 WORDS)